Linked Life Data

21526914

Source:http://linkedlifedata.com/resource/pubmed/id/21526914

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2011-4-29
pubmed:abstractText
Engineered myocardium may be used to repair myocardial defects. Although not clinically applicable yet, initial studies in rodents have demonstrated the feasibility of tissue engineering based myocardial repair in vivo. In order for restorative treatment to evolve into a functional treatment modality, tissue engineers have to generate human myocardium of sufficient size and with relevant contractile function to replace/repair myocardial defects. This requires the identification of a scalable and ideally autologous cardiomyocyte source as well as the development of strategies to overcome size limitations. We will further address pivotal issues pertaining to the allocation of suitable human cells for myocardial tissue engineering and discuss the translation of present myocardial tissue engineering concepts into preclinical, as well as clinical, trials.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1744-8298
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
435-45
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Cardiac tissue engineering: a clinical perspective.
pubmed:affiliation
Institute of Experimental and Clinical Pharmacology & Toxicology, University Medical Center Hamburg-Eppendorf, Germany. w.zimmermann@uke.uni-hamburg.de
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't